Keros Therapeutics voluntarily halts dosing of blood pressure treatment after safety review

Keros Therapeutics

12/12/2024 11:16

Dec 12 (Reuters) - Keros Therapeutics  KROS.O  said on
Thursday that it has voluntarily halted dosing of its 3.0
milligram (mg) and 4.5 mg doses of its high blood pressure
treatment in a mid-stage study based on a safety review. 

 (Reporting by Sneha S K; Editing by Abinaya Vijayaraghavan)
 ((Sneha.SK@thomsonreuters.com;))